Aimei Health Technology Co., Ltd. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; the company was incorporated April 27, 2023, so results cover inception through year-end, not a standalone fourth quarter. Aimei is a Nasdaq-listed blank-check company (SPAC), not an operating healthcare business. It completed its IPO on December 6, 2023 and had not identified a business-combination target by the filing date.
Financial results and position
| Metric | Period / date | Reported value |
|---|---|---|
| Operating revenue | Inception–December 31, 2023 | $0; no operations or operating revenue |
| Operating costs / operating loss | Inception–December 31, 2023 | $28,459 |
| Interest income from trust investments | Inception–December 31, 2023 | $199,848 |
| Net income | Inception–December 31, 2023 | $171,389, or $0.08 per basic and diluted share |
| Operating cash flow | Inception–December 31, 2023 | $0 |
| Investing cash flow | Inception–December 31, 2023 | $(69,690,000), primarily funds placed in trust |
| Cash and marketable securities in trust | December 31, 2023 | $69,889,848 |
| Cash outside trust | December 31, 2023 | $580,717 |
| Working capital | December 31, 2023 | Approximately $555,876 |
| Total liabilities | December 31, 2023 | $714,841, including $690,000 deferred underwriting fee |
| Long-term debt and other long-term obligations | December 31, 2023 | None reported |
The $69 million IPO raised gross proceeds; a concurrent private placement raised $3.32 million. IPO offering costs were $2,070,665, in addition to the deferred underwriting fee. A $210,151 sponsor note was repaid December 7, 2023; no working-capital loans were outstanding at year-end. Profitability and operating margins are not meaningful because the company had no operating revenue; reported net income arose from trust interest, not business operations. No comparable prior-year operating period is presented.
Business context, outlook, and material risks
- Management intends to seek a business combination, with a stated preference for small-cap healthcare innovation businesses in biopharmaceuticals, medical technology, diagnostics, and related services. Its search is not restricted to healthcare or a particular geography. No target had been selected and no substantive target discussions had occurred.
- The company generally has 12 months from the IPO closing to complete a combination, with up to twelve one-month extensions (up to 24 months total) subject to sponsor funding of $198,000 per month, or up to $227,700 per month if the over-allotment is exercised in full. The sponsor is not obligated to fund extensions. If no deal closes within the applicable period, public shares are to be redeemed and the company liquidated; rights may expire worthless.
- Nasdaq rules generally require a target’s fair market value to be at least 80% of the relevant trust balance when a definitive agreement is signed. Redemptions, dilution, and the need for additional financing could affect a transaction’s feasibility and value to continuing shareholders.
- Management believes available working capital and borrowing capacity are sufficient for current needs, but gives no assurance that additional financing will be available. The filing provides no post-combination financial guidance or operating forecast.
- The auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about going concern if a business combination is not completed in time. Management’s financial statements do not include adjustments for that uncertainty.
- Management concluded disclosure controls and procedures were not effective as of December 31, 2023. The filing does not include management’s ICFR assessment or an auditor attestation, citing the transition period for newly public companies.
- A potential China-related transaction could involve regulatory approval or filing uncertainty, data and cybersecurity rules, foreign-exchange controls, limits on moving cash offshore, and other PRC legal and policy risks. The company says it believes no PRC approval is currently required, but acknowledges authorities could take a different view. It states it will not combine with a target operating through VIEs.
- Other notable exposures include conflicts arising from directors’ and officers’ outside affiliations, sponsor incentives tied to founder shares, and possible creditor claims against trust assets. The company says its sponsor’s ability to satisfy its trust indemnity is unverified and likely limited.
Most important facts for investors to verify
- Confirm the trust balance, redemption value per public share, and the extension deadline and funding terms in current filings.
- Track any business-combination announcement, target valuation, financing needs, shareholder redemptions, and resulting dilution or control changes.
- Review remediation of the ineffective disclosure controls and any later disclosures about internal controls.
- Assess the sponsor’s capacity to meet its trust indemnity and any claims, fees, or other obligations that could reduce trust proceeds.
- For any China-linked target, verify applicable CSRC/CAC requirements, data and cybersecurity compliance, and practical ability to transfer cash and pay dividends offshore.